A combination of irinotecan/cisplatinum and irinotecan/temozolomide or tumor-targeting Salmonella typhimurium A1-R arrest doxorubicin- and temozolomide-resistant myxofibrosarcoma in a PDOX mouse model.

[1]  M. Unno,et al.  Oral recombinant methioninase (o-rMETase) is superior to injectable rMETase and overcomes acquired gemcitabine resistance in pancreatic cancer. , 2018, Cancer letters.

[2]  S. Dry,et al.  Combination therapy of tumor-targeting Salmonella typhimurium A1-R and oral recombinant methioninase regresses a BRAF-V600E-negative melanoma. , 2018, Biochemical and biophysical research communications.

[3]  Xiaoli Ren,et al.  Irinotecan-platinum combination therapy for previously untreated extensive-stage small cell lung cancer patients: a meta-analysis , 2018, BMC Cancer.

[4]  F. Nicolantonio,et al.  Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  Sakae Tanaka,et al.  Integrated genetic and epigenetic analysis of myxofibrosarcoma , 2018, Nature Communications.

[6]  I. Endo,et al.  Tumor-targeting Salmonella typhimurium A1-R suppressed an imatinib-resistant gastrointestinal stromal tumor with c-kit exon 11 and 17 mutations , 2018, Heliyon.

[7]  I. Endo,et al.  Patient-derived orthotopic xenograft models for cancer of unknown primary precisely distinguish chemotherapy, and tumor-targeting S. typhimurium A1-R is superior to first-line chemotherapy , 2018, Signal Transduction and Targeted Therapy.

[8]  S. Dry,et al.  Recombinant methioninase in combination with doxorubicin (DOX) overcomes first-line DOX resistance in a patient-derived orthotopic xenograft nude-mouse model of undifferentiated spindle-cell sarcoma. , 2018, Cancer letters.

[9]  S. Dry,et al.  Tumor-targeting Salmonella typhimurium A1-R is a highly effective general therapeutic for undifferentiated soft tissue sarcoma patient-derived orthotopic xenograft nude-mouse models. , 2018, Biochemical and biophysical research communications.

[10]  S. Ferrari,et al.  Irinotecan and temozolomide in recurrent Ewing sarcoma: an analysis in 51 adult and pediatric patients , 2018, Acta oncologica.

[11]  S. Hahn,et al.  Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer , 2018, Cancer research and treatment : official journal of Korean Cancer Association.

[12]  Haa-Na Song,et al.  Pembrolizumab for Refractory Metastatic Myxofibrosarcoma: A Case Report , 2018, Cancer research and treatment : official journal of Korean Cancer Association.

[13]  S. Dry,et al.  Intra-tumor L-methionine level highly correlates with tumor size in both pancreatic cancer and melanoma patient-derived orthotopic xenograft (PDOX) nude-mouse models , 2018, Oncotarget.

[14]  S. Dry,et al.  Temozolomide combined with irinotecan regresses a cisplatinum-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) precision-oncology mouse model , 2017, Oncotarget.

[15]  E. Stepanski,et al.  Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate‐grade or high‐grade liposarcoma , 2017, Cancer.

[16]  I. Endo,et al.  The combination of temozolomide-irinotecan regresses a doxorubicin-resistant patient-derived orthotopic xenograft (PDOX) nude-mouse model of recurrent Ewing’s sarcoma with a FUS-ERG fusion and CDKN2A deletion: Direction for third-line patient therapy , 2017, Oncotarget.

[17]  T. Kondo,et al.  Discoidin, CUB and LCCL domain-containing protein 2 (DCBLD2) is a novel biomarker of myxofibrosarcoma invasion identified by global protein expression profiling. , 2017, Biochimica et biophysica acta. Proteins and proteomics.

[18]  A. D. Dei Tos,et al.  Activity of anthracycline- and ifosfamide-based chemotherapy in a series of patients affected by advanced myxofibrosarcoma , 2017, Clinical Sarcoma Research.

[19]  S. Dry,et al.  Temozolomide combined with irinotecan caused regression in an adult pleomorphic rhabdomyosarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model , 2017, Oncotarget.

[20]  S. Dry,et al.  Tumor-targeting Salmonella typhimurium A1-R combined with temozolomide regresses malignant melanoma with a BRAF-V600E mutation in a patient-derived orthotopic xenograft (PDOX) model , 2016, Oncotarget.

[21]  M. Bouvet,et al.  Efficacy of Tumor-Targeting Salmonella A1-R on a Melanoma Patient-Derived Orthotopic Xenograft (PDOX) Nude-Mouse Model , 2016, PloS one.

[22]  Dong-Wan Kim,et al.  Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer , 2016, Cancer research and treatment : official journal of Korean Cancer Association.

[23]  P. Catalano,et al.  Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer , 2016, American journal of clinical oncology.

[24]  I. Endo,et al.  Tumor-targeting Salmonella typhimurium A1-R in combination with doxorubicin eradicate soft tissue sarcoma in a patient-derived orthotopic xenograft (PDOX) model , 2016, Oncotarget.

[25]  Narasimhan P. Agaram,et al.  Optimal Percent Myxoid Component to Predict Outcome in High-Grade Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma , 2016, Annals of Surgical Oncology.

[26]  R. Strowd,et al.  The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide , 2016, Journal of Neuro-Oncology.

[27]  R. Hoffman.  Patient-derived orthotopic xenografts: better mimic of metastasis than subcutaneous xenografts , 2015, Nature Reviews Cancer.

[28]  I. Endo,et al.  Tumor-Targeting Salmonella typhimurium A1-R in Combination with Trastuzumab Eradicates HER-2-Positive Cervical Cancer Cells in Patient-Derived Mouse Models , 2015, PloS one.

[29]  P. Meyers.  Systemic therapy for osteosarcoma and Ewing sarcoma. , 2015, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[30]  Yukihiko Hiroshima,et al.  Selective efficacy of zoledronic acid on metastasis in a patient‐derived orthotopic xenograph (PDOX) nude‐mouse model of human pancreatic cancer , 2015, Journal of surgical oncology.

[31]  I. Endo,et al.  Establishment of a Patient-Derived Orthotopic Xenograft (PDOX) Model of HER-2-Positive Cervical Cancer Expressing the Clinical Metastatic Pattern , 2015, PloS one.

[32]  F. Benariba,et al.  Myxofibrosarcoma of the thyroid gland. , 2014, European annals of otorhinolaryngology, head and neck diseases.

[33]  M. Bouvet,et al.  Tumor-targeting Salmonella typhimurium A1-R decoys quiescent cancer cells to cycle as visualized by FUCCI imaging and become sensitive to chemotherapy , 2014, Cell cycle.

[34]  I. Endo,et al.  Efficacy of Salmonella typhimurium A1‐R Versus Chemotherapy on a Pancreatic Cancer Patient‐Derived Orthotopic Xenograft (PDOX) , 2014, Journal of cellular biochemistry.

[35]  M. Takeuchi,et al.  Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: a randomised phase III trial (TCOG GI-0801/BIRIP trial). , 2014, European journal of cancer.

[36]  Y. Toyama,et al.  An analysis of factors related to recurrence of myxofibrosarcoma. , 2013, Japanese journal of clinical oncology.

[37]  C. Rodríguez-Galindo,et al.  Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma , 2013, Pediatric blood & cancer.

[38]  C. Morosi,et al.  Dacarbazine in Solitary Fibrous Tumor: A Case Series Analysis and Preclinical Evidence vis-à-vis Temozolomide and Antiangiogenics , 2013, Clinical Cancer Research.

[39]  J. Arrese,et al.  Myxofibrosarcoma: A Diagnostic Pitfall , 2013, Rare tumors.

[40]  V. Rusch,et al.  Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer , 2012, Cancer.

[41]  S. Singer,et al.  The enigma of myxofibrosarcoma of the extremity , 2012, Cancer.

[42]  A. Lazar,et al.  Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor , 2011, Cancer.

[43]  T. Choueiri,et al.  Pazopanib: Clinical development of a potent anti-angiogenic drug. , 2011, Critical reviews in oncology/hematology.

[44]  L. Mariani,et al.  Myxofibrosarcoma: Prognostic Factors and Survival in a Series of Patients Treated at a Single Institution , 2011, Annals of Surgical Oncology.

[45]  Fang Liu,et al.  Vessel destruction by tumor-targeting Salmonella typhimurium A1-R is enhanced by high tumor vascularity , 2010, Cell cycle.

[46]  M. Haider,et al.  Phase 2 trial of preoperative irinotecan plus cisplatin and conformal radiotherapy, followed by surgery for esophageal cancer , 2010, Cancer.

[47]  L. Wexler,et al.  Irinotecan and temozolomide for Ewing sarcoma: The Memorial Sloan‐Kettering experience , 2009, Pediatric blood & cancer.

[48]  C. Raut,et al.  Recurrence patterns and survival for patients with intermediate- and high-grade myxofibrosarcoma. , 2009, International journal of radiation oncology, biology, physics.

[49]  K. Yoshimura,et al.  [A case of retroperitoneal myxofibrosarcoma]. , 2009, Hinyokika kiyo. Acta urologica Japonica.

[50]  P. Hohenberger,et al.  Preoperative intensity-modulated radiotherapy combined with temozolomide for locally advanced soft-tissue sarcoma. , 2009, International journal of radiation oncology, biology, physics.

[51]  Sei Ueda,et al.  中咽頭 myxofibrosarcoma 例 , 2008 .

[52]  C. Fuchs,et al.  Irinotecan in the treatment of colorectal cancer. , 2006, Cancer treatment reviews.

[53]  J. Maurel,et al.  A phase II trial of temozolomide as a 6‐week, continuous, oral schedule in patients with advanced soft tissue sarcoma , 2005, Cancer.

[54]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[55]  A. Troxel,et al.  A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma , 2003, Cancer.

[56]  Y. Mizutani,et al.  Irinotecan plus cisplatin has substantial antitumor effect as salvage chemotherapy against germ cell tumors , 2002, Cancer.

[57]  N. Umesaki,et al.  Combination therapy with irinotecan and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer , 1999, British Journal of Cancer.

[58]  O. S. Nielsen,et al.  Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. , 1999, European journal of cancer.

[59]  R. Hoffman,et al.  A metastatic orthotopic-transplant nude-mouse model of human patient breast cancer. , 1993, Anticancer research.

[60]  R. Hoffman,et al.  Human ovarian carcinoma metastatic models constructed in nude mice by orthotopic transplantation of histologically-intact patient specimens. , 1993, Anticancer research.

[61]  R. Hoffman,et al.  Orthotopic transplantation of histologically intact clinical specimens of stomach cancer to nude mice: Correlation of metastatic sites in mouse and individual patient donors , 1993, International journal of cancer.

[62]  R. Hoffman,et al.  A new patient‐like metastatic model of human lung cancer constructed orthotopically with intact tissue via thoracotomy in immunodeficient mice , 1992, International journal of cancer.

[63]  R. Hoffman,et al.  Models of human metastatic colon cancer in nude mice orthotopically constructed by using histologically intact patient specimens. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[64]  J. Fortner,et al.  Surgical Treatment of 297 Soft Tissue Sarcomas of the Lower Extremity , 1975, Annals of surgery.

[65]  R. Hoffman,et al.  Tumor-targeting Salmonella typhimurium A1-R Inhibits Osteosarcoma Angiogenesis in the In Vivo Gelfoam® Assay Visualized by Color-coded Imaging. , 2018, Anticancer research.

[66]  M. Kalender,et al.  Irinotecan as a second-line monotherapy for small cell lung cancer. , 2011, Asian Pacific journal of cancer prevention : APJCP.